MediciNova. has filed a patent for an injectable pharmaceutical composition containing SBE-ß-CD and ibudilast or polyoxyl castor oil and ibudilast. The composition aims to provide a buffered aqueous solution for medical use. GlobalData’s report on MediciNova gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on MediciNova, Peptide pharmacophores was a key innovation area identified from patents. MediciNova's grant share as of January 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.
The patent application (Publication Number: US20240016729A1) discloses a pharmaceutical composition comprising a buffered aqueous solution containing sulfobutylether-ß-cyclodextrin (SBE-ß-CD) and ibudilast. The composition ranges from 5% w/v to 15% w/v SBE-ß-CD and 0.05% w/v to 0.5% w/v ibudilast. The solution also includes disodium phosphate and sodium dihydrogen phosphate in specific concentrations. Additionally, the patent outlines variations of the composition with different percentages of SBE-ß-CD, ibudilast, and other components, tailored for specific medical conditions.
Furthermore, the patent covers methods of treating neurodegenerative diseases, acute lung injury, and cancer by administering the disclosed pharmaceutical composition to patients in need. The composition can be used as an injectable solution for targeted delivery. The patent's detailed description of the composition's components and their specific concentrations provides a basis for its potential therapeutic applications in various medical conditions. The patent's claims offer a comprehensive overview of the pharmaceutical composition's formulation and its potential use in treating specific diseases, highlighting its versatility and potential impact in the field of medicine.
To know more about GlobalData’s detailed insights on MediciNova, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
